Back to Search
Start Over
Management of Atrial Fibrillation in COVID-19 Pandemic.
- Source :
-
Circulation journal : official journal of the Japanese Circulation Society [Circ J] 2020 Sep 25; Vol. 84 (10), pp. 1679-1685. Date of Electronic Publication: 2020 Sep 09. - Publication Year :
- 2020
-
Abstract
- The health crisis due to coronavirus disease 2019 (COVID-19) has shocked the world, with more than 1 million infections and casualties. COVID-19 can present from mild illness to multi-organ involvement, but especially acute respiratory distress syndrome. Cardiac injury and arrhythmias, including atrial fibrillation (AF), are not uncommon in COVID-19. COVID-19 is highly contagious, and therapy against the virus remains premature and largely unknown, which makes the management of AF patients during the pandemic particularly challenging. We describe a possible pathophysiological link between COVID-19 and AF, and therapeutic considerations for AF patients during this pandemic.
- Subjects :
- Angiotensin-Converting Enzyme 2
Atrial Fibrillation physiopathology
COVID-19
Catheter Ablation methods
Coronavirus Infections physiopathology
Coronavirus Infections virology
Cytokines blood
Drug Interactions
Humans
Pandemics
Peptidyl-Dipeptidase A metabolism
Pneumonia, Viral physiopathology
Pneumonia, Viral virology
Risk
SARS-CoV-2
COVID-19 Drug Treatment
Adrenergic beta-Antagonists therapeutic use
Anti-Arrhythmia Agents therapeutic use
Anticoagulants therapeutic use
Antiviral Agents therapeutic use
Atrial Fibrillation drug therapy
Betacoronavirus
Coronavirus Infections drug therapy
Coronavirus Infections epidemiology
Pneumonia, Viral drug therapy
Pneumonia, Viral epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1347-4820
- Volume :
- 84
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Circulation journal : official journal of the Japanese Circulation Society
- Publication Type :
- Academic Journal
- Accession number :
- 32908073
- Full Text :
- https://doi.org/10.1253/circj.CJ-20-0566